New and emerging biomarkers in left ventricular systolic dysfunction-insight into dilated cardiomyopathy

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 516-527

  Gopal, Deepa M ^a   Sam, Flora ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Dilated cardiomyopathy; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BETA TRACE PROTEIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIOTROPHIN 1; FOLLISTATIN LIKE 1; FOLLISTATIN RELATED PROTEIN; GALECTIN 3; GLYCOPROTEIN; INTERLEUKIN 1 RECEPTOR; KIDNEY INJURY MOLECULE 1; MYOSTATIN; NEUROHORMONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPROTEGERIN; PENTRAXIN 3; ST2 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARDIAC INTERSTITIUM; CELL DAMAGE; CELL ELONGATION; CELL ENERGY; CELL STRESS; CONGESTIVE CARDIOMYOPATHY; HEART MUSCLE CELL; HUMAN; INFLAMMATION; INTERSTITIUM; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; HUMANS; MYOCYTES, CARDIAC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84880511920     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9462-3     Document Type: Article

References (134)

1. Maron, B. J.; Towbin, J. A.; Thiene, G.; Antzelevitch, C.; Corrado, D.; Arnett, D.; Moss, A. J.; Seidman, C. E.; Young, J. B.; American Heart Association, Council on Clinical Cardiology, Heart Failure, Transplantation Committe, Quality of Care, Outcomes Research, Functional Genomics, Translational Biology Interdisciplinary Working Group, & Council on Epidemiology Prevention. (2006). Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807-1816.
2. Richardson, P.; McKenna, W.; Bristow, M.; Maisch, B.; Mautner, B.; O'Connell, J.; Olsen, E.; Thiene, G.; Goodwin, J.; Gyarfas, I.; Martin, I.; & Nordet, P. (1996). Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation, 93, 841-842.
3. Lang, R. M.; Bierig, M.; Devereux, R. B.; Flachskampf, F. A.; Foster, E.; Pellikka, P. A.; Picard, M. H.; Roman, M. J.; Seward, J.; Shanewise, J. S.; Solomon, S. D.; Spencer, K. T.; Sutton, M. S.; Stewart, W. J.; Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines, Standards Committee, & European Association of Echocardiography. (2005). Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association Of Echocardiography, a branch of the European Society Of Cardiology. Journal of the American Society of Echocardiography, 18, 1440-1463.
4. Davies, M. J.; & McKenna, W. J. (1994). Dilated cardiomyopathy: An introduction to pathology and pathogenesis. British Heart Journal, 72, S24.
5. Maisel, A. S.; Krishnaswamy, P.; Nowak, R. M.; McCord, J.; Hollander, J. E.; Duc, P.; Omland, T.; Storrow, A. B.; Abraham, W. T.; Wu, A. H.; Clopton, P.; Steg, P. G.; Westheim, A.; Knudsen, C. W.; Perez, A.; Kazanegra, R.; Herrmann, H. C.; McCullough, P. A.; & Breathing Not Properly Multinational Study Investigators. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine, 347, 161-167.
6. Januzzi, J. L.; Jr.; Camargo, C. A.; Anwaruddin, S.; Baggish, A. L.; Chen, A. A.; Krauser, D. G.; Tung, R.; Cameron, R.; Nagurney, J. T.; Chae, C. U.; Lloyd-Jones, D. M.; Brown, D. F.; Foran-Melanson, S.; Sluss, P. M.; Lee-Lewandrowski, E.; & Lewandrowski, K. B. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The American Journal of Cardiology, 95, 948-954.
7. Maisel, A. S.; McCord, J.; Nowak, R. M.; Hollander, J. E.; Wu, A. H.; Duc, P.; Omland, T.; Storrow, A. B.; Krishnaswamy, P.; Abraham, W. T.; Clopton, P.; Steg, G.; Aumont, M. C.; Westheim, A.; Knudsen, C. W.; Perez, A.; Kamin, R.; Kazanegra, R.; Herrmann, H. C.; McCullough, P. A.; & Breathing Not Properly Multinational Study Investigators. (2003). Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol, 41, 2010-2017.
8. O'Donoghue, M.; Chen, A.; Baggish, A. L.; Anwaruddin, S.; Krauser, D. G.; Tung, R.; & Januzzi, J. L. (2005). The effects of ejection fraction on N-terminal proBNP and BNP levels in patients with acute CHF: Analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Journal of Cardiac Failure, 11, S9-S14.
9. Steg, P. G.; Joubin, L.; McCord, J.; Abraham, W. T.; Hollander, J. E.; Omland, T.; Mentre, F.; McCullough, P. A.; & Maisel, A. S. (2005). B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest, 128, 21-29.
10. Felker, G. M.; Hasselblad, V.; Hernandez, A. F.; & O'Connor, C. M. (2009). Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. American Heart Journal, 158, 422-430.
11. Januzzi, J. L.; Jr.; Rehman, S. U.; Mohammed, A. A.; Bhardwaj, A.; Barajas, L.; Barajas, J.; Kim, H. N.; Baggish, A. L.; Weiner, R. B.; Chen-Tournoux, A.; Marshall, J. E.; Moore, S. A.; Carlson, W. D.; Lewis, G. D.; Shin, J.; Sullivan, D.; Parks, K.; Wang, T. J.; Gregory, S. A.; Uthamalingam, S.; & Semigran, M. J. (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol, 58, 1881-1889.
12. Macheret, F.; Boerrigter, G.; McKie, P.; Costello-Boerrigter, L.; Lahr, B.; Heublein, D.; Sandberg, S.; Ikeda, Y.; Cataliotti, A.; Bailey, K.; Rodeheffer, R.; & Burnett, J. C.; Jr. (2011). Pro-B-type natriuretic peptide(1-108) circulates in the general community: Plasma determinants and detection of left ventricular dysfunction. Journal of the American College of Cardiology, 57, 1386-1395.
13. Costello-Boerrigter, L. C.; Boerrigter, G.; Redfield, M. M.; Rodeheffer, R. J.; Urban, L. H.; Mahoney, D. W.; Jacobsen, S. J.; Heublein, D. M.; & Burnett, J. C.; Jr. (2006). Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. Journal of the American College of Cardiology, 47, 345-353.
14. Redfield, M. M.; Rodeheffer, R. J.; Jacobsen, S. J.; Mahoney, D. W.; Bailey, K. R.; & Burnett, J. C.; Jr. (2002). Plasma brain natriuretic peptide concentration: Impact of age and gender. Journal of the American College of Cardiology, 40, 976-982.
15. Yoshimura, M.; Yasue, H.; & Ogawa, H. (2001). Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Canadian Journal of Physiology and Pharmacology, 79, 730-735.
16. Morgenthaler, N. G.; Struck, J.; Thomas, B.; & Bergmann, A. (2004). Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clinical Chemistry, 50, 234-236.
17. Moertl, D.; Berger, R.; Struck, J.; Gleiss, A.; Hammer, A.; Morgenthaler, N. G.; Bergmann, A.; Huelsmann, M.; & Pacher, R. (2009). Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: Influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. Journal of the American College of Cardiology, 53, 1783-1790.
18. von Haehling, S.; Jankowska, E. A.; Morgenthaler, N. G.; Vassanelli, C.; Zanolla, L.; Rozentryt, P.; Filippatos, G. S.; Doehner, W.; Koehler, F.; Papassotiriou, J.; Kremastinos, D. T.; Banasiak, W.; Struck, J.; Ponikowski, P.; Bergmann, A.; & Anker, S. D. (2007). Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. Journal of the American College of Cardiology, 50, 1973-1980.
19. Weinberg, E. O.; Shimpo, M.; De Keulenaer, G. W.; MacGillivray, C.; Tominaga, S.; Solomon, S. D.; Rouleau, J. L.; & Lee, R. T. (2002). Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation, 106, 2961-2966.
20. Sanada, S.; Hakuno, D.; Higgins, L. J.; Schreiter, E. R.; McKenzie, A. N.; & Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation, 117, 1538-1549.
21. Pascual-Figal, D. A.; Ordonez-Llanos, J.; Tornel, P. L.; Vazquez, R.; Puig, T.; Valdes, M.; Cinca, J.; de Luna, A. B.; Bayes-Genis, A.; & Investigators, M. (2009). Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Journal of the American College of Cardiology, 54, 2174-2179.
22. Ky, B.; French, B.; McCloskey, K.; Rame, J. E.; McIntosh, E.; Shahi, P.; Dries, D. L.; Tang, W. H.; Wu, A. H.; Fang, J. C.; Boxer, R.; Sweitzer, N. K.; Levy, W. C.; Goldberg, L. R.; Jessup, M.; & Cappola, T. P. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation. Heart Failure, 4, 180-187.
23. Shah, R. V.; Chen-Tournoux, A. A.; Picard, M. H.; van Kimmenade, R. R.; & Januzzi, J. L. (2009). Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circulation. Heart Failure, 2, 311-319.
24. Jungbauer, C. G.; Riedlinger, J.; Buchner, S.; Birner, C.; Resch, M.; Lubnow, M.; Debl, K.; Buesing, M.; Huedig, H.; Riegger, G.; & Luchner, A. (2011). High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-B-type natriuretic peptide. Clinical Chemistry and Laboratory Medicine, 49, 1899-1906.
25. Sato, Y.; Fujiwara, H.; & Takatsu, Y. (2012). Cardiac troponin and heart failure in the era of high-sensitivity assays. Journal of Cardiology, 60, 160-167.
26. Schaap, F. G.; van der Vusse, G. J.; & Glatz, J. F. (1998). Fatty acid-binding proteins in the heart. Molecular and Cellular Biochemistry, 180, 43-51.
27. Niizeki, T.; Takeishi, Y.; Arimoto, T.; Takabatake, N.; Nozaki, N.; Hirono, O.; Watanabe, T.; Nitobe, J.; Harada, M.; Suzuki, S.; Koyama, Y.; Kitahara, T.; Sasaki, T.; & Kubota, I. (2007). Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. Journal of Cardiac Failure, 13, 120-127.
28. Setsuta, K.; Seino, Y.; Ogawa, T.; Arao, M.; Miyatake, Y.; & Takano, T. (2002). Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. American Journal of Medicine, 113, 717-722.
29. Arimoto, T.; Takeishi, Y.; Shiga, R.; Fukui, A.; Tachibana, H.; Nozaki, N.; Hirono, O.; Nitobe, J.; Miyamoto, T.; Hoit, B. D.; & Kubota, I. (2005). Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. Journal of Cardiac Failure, 11, 56-60.
30. Niessner, A.; Hohensinner, P. J.; Rychli, K.; Neuhold, S.; Zorn, G.; Richter, B.; Hulsmann, M.; Berger, R.; Mortl, D.; Huber, K.; Wojta, J.; & Pacher, R. (2009). Prognostic value of apoptosis markers in advanced heart failure patients. European Heart Journal, 30, 789-796.
31. Kinugawa, T.; Kato, M.; Yamamoto, K.; Hisatome, I.; & Nohara, R. (2012). Proinflammatory cytokine activation is linked to apoptotic mediator, soluble fas level in patients with chronic heart failure. International Heart Journal, 53, 182-186.
32. McPherron, A. C.; Lawler, A. M.; & Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83-90.
33. George, I.; Bish, L. T.; Kamalakkannan, G.; Petrilli, C. M.; Oz, M. C.; Naka, Y.; Sweeney, H. L.; & Maybaum, S. (2010). Myostatin activation in patients with advanced heart failure and after mechanical unloading. European Journal of Heart Failure, 12, 444-453.
34. Sharma, M.; Kambadur, R.; Matthews, K. G.; Somers, W. G.; Devlin, G. P.; Conaglen, J. V.; Fowke, P. J.; & Bass, J. J. (1999). Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. Journal of Cellular Physiology, 180, 1-9.
35. Gruson, D.; Ahn, S. A.; Ketelslegers, J. M.; & Rousseau, M. F. (2011). Increased plasma myostatin in heart failure. European Journal of Heart Failure, 13, 734-736.
36. Thomas, C. V.; Coker, M. L.; Zellner, J. L.; Handy, J. R.; Crumbley, A. J.; 3rd, & Spinale, F. G. (1998). Increased matrix metalloproteinase activity and selective upregulation in lv myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 97, 1708-1715.
37. Spinale, F. G.; Coker, M. L.; Heung, L. J.; Bond, B. R.; Gunasinghe, H. R.; Etoh, T.; Goldberg, A. T.; Zellner, J. L.; & Crumbley, A. J. (2000). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 102, 1944-1949.
38. Eckhouse, S. R.; & Spinale, F. G. (2012). Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Failure Clinics, 8, 7-20.
39. Spinale, F. G. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiological Reviews, 87, 1285-1342.
40. Li, Y. Y.; Feldman, A. M.; Sun, Y.; & McTiernan, C. F. (1998). Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation, 98, 1728-1734.
41. Cicoira, M.; Rossi, A.; Bonapace, S.; Zanolla, L.; Golia, G.; Franceschini, L.; Caruso, B.; Marino, P. N.; & Zardini, P. (2004). Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. Journal of Cardiac Failure, 10, 403-411.
42. Sundstrom, J.; Evans, J. C.; Benjamin, E. J.; Levy, D.; Larson, M. G.; Sawyer, D. B.; Siwik, D. A.; Colucci, W. S.; Wilson, P. W.; & Vasan, R. S. (2004). Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: The Framingham Heart Study. European Heart Journal, 25, 1509-1516.
43. Bruggink, A. H.; van Oosterhout, M. F.; de Jonge, N.; Ivangh, B.; van Kuik, J.; Voorbij, R. H.; Cleutjens, J. P.; Gmelig-Meyling, F. H.; & de Weger, R. A. (2006). Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. The Journal of Heart and Lung Transplantation, 25, 1091-1098.
44. Liu, Y. H.; D'Ambrosio, M.; Liao, T. D.; Peng, H.; Rhaleb, N. E.; Sharma, U.; Andre, S.; Gabius, H. J.; & Carretero, O. A. (2009). N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. American Journal of Physiology - Heart and Circulatory Physiology, 296, H404-H412.
45. Sharma, U. C.; Pokharel, S.; van Brakel, T. J.; van Berlo, J. H.; Cleutjens, J. P.; Schroen, B.; Andre, S.; Crijns, H. J.; Gabius, H. J.; Maessen, J.; & Pinto, Y. M. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 110, 3121-3128.
46. Lopez-Andres, N.; Rossignol, P.; Iraqi, W.; Fay, R.; Nuee, J.; Ghio, S.; Cleland, J. G.; Zannad, F.; & Lacolley, P. (2012). Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 14, 74-81.
47. Lok, D. J.; Lok, S. I.; Bruggink-Andre de la Porte, P. W.; Badings, E.; Lipsic, E.; van Wijngaarden, J.; de Boer, R. A.; van Veldhuisen, D. J.; van der Meer, P. (2012). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical Research in Cardiology, 102, 103-110.
48. Ho, J. E.; Liu, C.; Lyass, A.; Courchesne, P.; Pencina, M. J.; Vasan, R. S.; Larson, M. G.; & Levy, D. (2012). Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. Journal of the American College of Cardiology, 60, 1249-1256.
49. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; & Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 323, 236-241.
50. Mann, D. L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988-998.
51. Ren, M. Y.; & Sui, S. J. (2012). The role of TWEAK/Fn14 in cardiac remodeling. Molecular Biology Reports, 39, 9971-9977.
52. Chorianopoulos, E.; Rosenberg, M.; Zugck, C.; Wolf, J.; Katus, H. A.; & Frey, N. (2009). Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. European Journal of Heart Failure, 11, 1050-1056.
53. Richter, B.; Rychli, K.; Hohensinner, P. J.; Berger, R.; Mortl, D.; Neuhold, S.; Zorn, G.; Huber, K.; Maurer, G.; Wojta, J.; Pacher, R.; Hulsmann, M.; & Niessner, A. (2010). Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis, 213, 545-548.
54. Ueland, T.; Yndestad, A.; Oie, E.; Florholmen, G.; Halvorsen, B.; Froland, S. S.; Simonsen, S.; Christensen, G.; Gullestad, L.; & Aukrust, P. (2005). Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation, 111, 2461-2468.
55. Roysland, R.; Masson, S.; Omland, T.; Milani, V.; Bjerre, M.; Flyvbjerg, A.; Di Tano, G.; Misuraca, G.; Maggioni, A. P.; Tognoni, G.; Tavazzi, L.; Latini, R.; & Investigators, G.-H. (2010). Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. American Heart Journal, 160, 286-293.
56. Bottazzi, B.; Doni, A.; Garlanda, C.; & Mantovani, A. (2010). An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annual Review of Immunology, 28, 157-183.
57. Latini, R.; Gullestad, L.; Masson, S.; Nymo, S. H.; Ueland, T.; Cuccovillo, I.; Vardal, M.; Bottazzi, B.; Mantovani, A.; Lucci, D.; Masuda, N.; Sudo, Y.; Wikstrand, J.; Tognoni, G.; Aukrust, P.; Tavazzi, L.; et al. (2012). Pentraxin-3 in chronic heart failure: The CORONA and GISSI-HF trials. European Journal of Heart Failure, 14, 992-999.
58. Suzuki, S.; Takeishi, Y.; Niizeki, T.; Koyama, Y.; Kitahara, T.; Sasaki, T.; Sagara, M.; & Kubota, I. (2008). Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal, 155, 75-81.
59. Tsutamoto, T.; Wada, A.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Fujii, M.; Matsumoto, T.; Yamamoto, T.; Wang, X.; Asai, S.; Tsuji, T.; Tanaka, H.; Saito, Y.; Kuwahara, K.; Nakao, K.; & Kinoshita, M. (2001). Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 38, 1485-1490.
60. Braunwald, E. (2008). Biomarkers in heart failure. The New England Journal of Medicine, 358, 2148-2159.
61. Steinberg, S. F. (2013). Oxidative stress and sarcomeric proteins. Circulation Research, 112, 393-405.
62. Vasilyev, N.; Williams, T.; Brennan, M. L.; Unzek, S.; Zhou, X.; Heinecke, J. W.; Spitz, D. R.; Topol, E. J.; Hazen, S. L.; & Penn, M. S. (2005). Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation, 112, 2812-2820.
63. Nicholls, S. J.; & Hazen, S. L. (2005). Myeloperoxidase and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1102-1111.
64. Tang, W. H.; Tong, W.; Troughton, R. W.; Martin, M. G.; Shrestha, K.; Borowski, A.; Jasper, S.; Hazen, S. L.; & Klein, A. L. (2007). Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. Journal of the American College of Cardiology, 49, 2364-2370.
65. Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; & Stefanadis, C. (2010). Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. Atherosclerosis, 210, 194-198.
66. Tsutamoto, T.; Wada, A.; Matsumoto, T.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Yamamoto, T.; Horie, H.; Sugimoto, Y.; & Kinoshita, M. (2001). Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 37, 2086-2092.
67. Yamaji, M.; Tsutamoto, T.; Kawahara, C.; Nishiyama, K.; Yamamoto, T.; Fujii, M.; & Horie, M. (2009). Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: The impact of oxidative stress. Circulation. Heart Failure, 2, 608-615.
68. Tsutsui, T.; Tsutamoto, T.; Wada, A.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Ohnishi, M.; & Kinoshita, M. (2002). Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of the American College of Cardiology, 39, 957-962.
69. Taegtmeyer, H. (2004). Cardiac metabolism as a target for the treatment of heart failure. Circulation, 110, 894-896.
70. Neubauer, S. (2007). The failing heart - An engine out of fuel. The New England Journal of Medicine, 356, 1140-1151.
71. Biolo, A.; Shibata, R.; Ouchi, N.; Kihara, S.; Sonoda, M.; Walsh, K.; & Sam, F. (2010). Determinants of adiponectin levels in patients with chronic systolic heart failure. The American Journal of Cardiology, 105, 1147-1152.
72. Frankel, D. S.; Vasan, R. S.; D'Agostino, R. B.; Sr.; Benjamin, E. J.; Levy, D.; Wang, T. J.; & Meigs, J. B. (2009). Resistin, adiponectin, and risk of heart failure the Framingham offspring study. Journal of the American College of Cardiology, 53, 754-762.
73. Nanayakkara, G.; Kariharan, T.; Wang, L.; Zhong, J.; & Amin, R. (2012). The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis.; 2, 253-266.
74. Khan, R. S.; Kato, T. S.; Chokshi, A.; Chew, M.; Yu, S.; Wu, C.; Singh, P.; Cheema, F. H.; Takayama, H.; Harris, C.; Reyes-Soffer, G.; Knoll, R.; Milting, H.; Naka, Y.; Mancini, D.; & Schulze, P. C. (2012). Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: Correction after ventricular assist device implantation. Circulation. Heart Failure, 5, 340-348.
75. Schulze, P. C.; Biolo, A.; Gopal, D.; Shahzad, K.; Balog, J.; Fish, M.; Siwik, D.; & Colucci, W. S. (2011). Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. Journal of Cardiac Failure, 17, 1004-1011.
76. Hopkins, T. A.; Ouchi, N.; Shibata, R.; & Walsh, K. (2007). Adiponectin actions in the cardiovascular system. Cardiovascular Research, 74, 11-18.
77. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; & Matsuzawa, Y. (2000). Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1595-1599.
78. Iwashima, Y.; Katsuya, T.; Ishikawa, K.; Ouchi, N.; Ohishi, M.; Sugimoto, K.; Fu, Y.; Motone, M.; Yamamoto, K.; Matsuo, A.; Ohashi, K.; Kihara, S.; Funahashi, T.; Rakugi, H.; Matsuzawa, Y.; & Ogihara, T. (2004). Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension, 43, 1318-1323.
79. Kumada, M.; Kihara, S.; Sumitsuji, S.; Kawamoto, T.; Matsumoto, S.; Ouchi, N.; Arita, Y.; Okamoto, Y.; Shimomura, I.; Hiraoka, H.; Nakamura, T.; Funahashi, T.; Matsuzawa, Y.; & for the Osaka CAD Study Group. (2003). Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol.; 23, 85-89.
80. Kistorp, C.; Faber, J.; Galatius, S.; Gustafsson, F.; Frystyk, J.; Flyvbjerg, A.; & Hildebrandt, P. (2005). Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 112, 1756-1762.
81. Haugen, E.; Furukawa, Y.; Isic, A.; & Fu, M. (2008). Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study. International Journal of Cardiology, 125, 216-219.
82. George, J.; Patal, S.; Wexler, D.; Sharabi, Y.; Peleg, E.; Kamari, Y.; Grossman, E.; Sheps, D.; Keren, G.; & Roth, A. (2006). Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 92, 1420-1424.
83. Takano, H.; Obata, J. E.; Kodama, Y.; Kitta, Y.; Nakamura, T.; Mende, A.; Kawabata, K.; Saito, Y.; Fujioka, D.; Kobayashi, T.; Yano, T.; Sano, K.; & Kugiyama, K. (2009). Adiponectin is released from the heart in patients with heart failure. International Journal of Cardiology, 132, 221-226.
84. Potocki, M.; Ziller, R.; & Mueller, C. (2012). Mid-regional pro-adrenomedullin in acute heart failure: A better biomarker or just another biomarker? Current Heart Failure Reports, 9, 244-251.
85. Adlbrecht, C.; Hulsmann, M.; Strunk, G.; Berger, R.; Mortl, D.; Struck, J.; Morgenthaler, N. G.; Bergmann, A.; Jakowitsch, J.; Maurer, G.; Lang, I. M.; & Pacher, R. (2009). Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. European Journal of Heart Failure, 11, 361-366.
86. Neuhold, S.; Huelsmann, M.; Strunk, G.; Stoiser, B.; Struck, J.; Morgenthaler, N. G.; Bergmann, A.; Moertl, D.; Berger, R.; & Pacher, R. (2008). Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: Prediction of death at different stages of the disease. Journal of the American College of Cardiology, 52, 266-272.
87. Voors, A. A.; von Haehling, S.; Anker, S. D.; Hillege, H. L.; Struck, J.; Hartmann, O.; Bergmann, A.; Squire, I.; van Veldhuisen, D. J.; Dickstein, K.; & Investigators, O. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. European Heart Journal, 30, 1187-1194.
88. Carubelli, V.; Metra, M.; Lombardi, C.; Bettari, L.; Bugatti, S.; Lazzarini, V.; & Dei, C. L. (2012). Renal dysfunction in acute heart failure: Epidemiology, mechanisms and assessment. Hear Fail Rev, 17, 271-282.
89. Schmidt-Ott, K. M.; Mori, K.; Li, J. Y.; Kalandadze, A.; Cohen, D. J.; Devarajan, P.; & Barasch, J. (2007). Dual action of neutrophil gelatinase-associated lipocalin. Journal of the American Society of Nephrology, 18, 407-413.
90. Maisel, A. S.; Mueller, C.; Fitzgerald, R.; Brikhan, R.; Hiestand, B. C.; Iqbal, N.; Clopton, P.; & van Veldhuisen, D. J. (2011). Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European Journal of Heart Failure, 13, 846-851.
91. Shrestha, K.; Shao, Z.; Singh, D.; Dupont, M.; & Tang, W. H. (2012). Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. The American Journal of Cardiology, 110, 1329-1335.
92. Shrestha, K.; Borowski, A. G.; Troughton, R. W.; Klein, A. L.; & Tang, W. H. (2012). Association between systemic neutrophil gelatinase- associated lipocalin and anemia, relative hypochromia, and inflammation in chronic systolic heart failure. Congestive Heart Failure, 18, 239-244.
93. Chen, H. H. (2011). Beta-trace protein versus cystatin C: Which is a better surrogate marker of renal function versus prognostic indicator in cardiovascular diseases? Journal of the American College of Cardiology, 57, 859-860.
94. Damman, K.; Van Veldhuisen, D. J.; Navis, G.; Vaidya, V. S.; Smilde, T. D.; Westenbrink, B. D.; Bonventre, J. V.; Voors, A. A.; & Hillege, H. L. (2010). Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 96, 1297-1302.
95. Wang, T. J.; Wollert, K. C.; Larson, M. G.; Coglianese, E.; McCabe, E. L.; Cheng, S.; Ho, J. E.; Fradley, M. G.; Ghorbani, A.; Xanthakis, V.; Kempf, T.; Benjamin, E. J.; Levy, D.; Vasan, R. S.; & Januzzi, J. L. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation, 126, 1596-1604.
96. Lok, S. I.; Winkens, B.; Goldschmeding, R.; van Geffen, A. J.; Nous, F. M.; van Kuik, J.; van der Weide, P.; Klopping, C.; Kirkels, J. H.; Lahpor, J. R.; Doevendans, P. A.; de Jonge, N.; & de Weger, R. A. (2012). Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. European Journal of Heart Failure, 14, 1249-1256.
97. Kawabata, D.; Tanaka, M.; Fujii, T.; Umehara, H.; Fujita, Y.; Yoshifuji, H.; Mimori, T.; & Ozaki, S. (2004). Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis and Rheumatism, 50, 660-668.
98. Le Luduec, J. B.; Condamine, T.; Louvet, C.; Thebault, P.; Heslan, J. M.; Heslan, M.; Chiffoleau, E.; & Cuturi, M. C. (2008). An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. American Journal of Transplantation, 8, 2297-2306.
99. Miyamae, T.; Marinov, A. D.; Sowders, D.; Wilson, D. C.; Devlin, J.; Boudreau, R.; Robbins, P.; & Hirsch, R. (2006). Follistatin-like protein-1 is a novel proinflammatory molecule. Journal of Immunology, 177, 4758-4762.
100. El-Armouche, A.; Ouchi, N.; Tanaka, K.; Doros, G.; Wittkopper, K.; Schulze, T.; Eschenhagen, T.; Walsh, K.; & Sam, F. (2011). Follistatin-like 1 in chronic systolic heart failure: A marker of left ventricular remodeling. Circulation. Heart Failure, 4, 621-627.
101. Lara-Pezzi, E.; Felkin, L. E.; Birks, E. J.; Sarathchandra, P.; Panse, K. D.; George, R.; Hall, J. L.; Yacoub, M. H.; Rosenthal, N.; & Barton, P. J.
102. de Boer, R. A.; Lok, D. J.; Jaarsma, T.; van der Meer, P.; Voors, A. A.; Hillege, H. L.; & van Veldhuisen, D. J. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 43, 60-68.
103. Grewal, J.; McKelvie, R.; Lonn, E.; Tait, P.; Carlsson, J.; Gianni, M.; Jarnert, C.; & Persson, H. (2008). BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. European Journal of Heart Failure, 10, 252-259.
104. Grewal, J.; McKelvie, R. S.; Persson, H.; Tait, P.; Carlsson, J.; Swedberg, K.; Ostergren, J.; & Lonn, E. (2008). Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. The American Journal of Cardiology, 102, 733-737.
105. Manzano-Fernandez, S.; Mueller, T.; Pascual-Figal, D.; Truong, Q. A.; & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107, 259-267.
106. Matsubara, J.; Sugiyama, S.; Nozaki, T.; Sugamura, K.; Konishi, M.; Ohba, K.; Matsuzawa, Y.; Akiyama, E.; Yamamoto, E.; Sakamoto, K.; Nagayoshi, Y.; Kaikita, K.; Sumida, H.; Kim-Mitsuyama, S.; & Ogawa, H. (2011). Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. Journal of the American College of Cardiology, 57, 861-869.
107. McKelvie, R. S.; Komajda, M.; McMurray, J.; Zile, M.; Ptaszynska, A.; Donovan, M.; Carson, P.; Massie, B. M.; & Investigators, I. P. (2010). Baseline plasma NT-proBNP and clinical characteristics: Results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure, 16, 128-134.
108. Chu, J. W.; Jones, G. T.; Tarr, G. P.; Phillips, L. V.; Wilkins, G. T.; van Rij, A. M.; Williams, M. J. (2012). Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. International Journal of Cardiology. doi: 10.1016/j.ijcard.2012.03.147.
109. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Murphy, N. F.; Conlon, C.; Patle, A.; Donnelly, S. C.; & McDonald, K. (2009). Diagnosis of heart failure with preserved ejection fraction: Improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 11, 191-197.
110. Roysland, R.; Bonaca, M. P.; Omland, T.; Sabatine, M.; Murphy, S. A.; Scirica, B. M.; Bjerre, M.; Flyvbjerg, A.; Braunwald, E.; & Morrow, D. A. (2012). Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart, 98, 786-791.
111. Ueland, T.; Dahl, C. P.; Kjekshus, J.; Hulthe, J.; Bohm, M.; Mach, F.; Goudev, A.; Lindberg, M.; Wikstrand, J.; Aukrust, P.; & Gullestad, L. (2011). Osteoprotegerin predicts progression of chronic heart failure: Results from CORONA. Circulation. Heart Failure, 4, 145-152.
112. Palladini, G.; Barassi, A.; Perlini, S.; Milani, P.; Foli, A.; Russo, P.; Albertini, R.; Obici, L.; Lavatelli, F.; Sarais, G.; Casarini, S.; Moratti, R.; Melzi d'Eril, G. V.; & Merlini, G. (2011). Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid.; 18, 216-221.
113. Carlsson, A. C.; Larsson, A.; Helmersson-Karlqvist, J.; Lind, L.; Ingelsson, E.; Larsson, T. E.; Sundstrom, J.; Arnlov, J. (2012). Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. European Journal of Heart Failure, 15, 441-446.
114. Ky, B.; French, B.; Levy, W. C.; Sweitzer, N. K.; Fang, J. C.; Wu, A. H.; Goldberg, L. R.; Jessup, M.; & Cappola, T. P. (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circulation. Heart Failure, 5, 183-190.
115. Tanaka, K.; Essick, E. E.; Doros, G.; Tanriverdi, K.; Connors, L. H.; Seldin, D. C.; Sam, F. (2013). Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. Journal of the American Heart Association, 2(2), e005868. doi: 10.1161/JAHA.112.005868.
116. Amir, O.; Rogowski, O.; David, M.; Lahat, N.; Wolff, R.; & Lewis, B. S. (2010). Circulating interleukin-10: Association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. The Israel Medical Association Journal, 12, 158-162.
117. Miettinen, K. H.; Lassus, J.; Harjola, V. P.; Siirila-Waris, K.; Melin, J.; Punnonen, K. R.; Nieminen, M. S.; Laakso, M.; & Peuhkurinen, K. J. (2008). Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. European Journal of Heart Failure, 10, 396-403.
118. Savic-Radojevic, A.; Radovanovic, S.; Pekmezovic, T.; Pljesa-Ercegovac, M.; Simic, D.; Djukic, T.; Matic, M.; Simic, T. (2013). The role of serum VCAM-1 and TNF-alpha as predictors of mortality and morbidity in patients with chronic heart failure. Journal of Clinical Laboratory Analysis, 27, 105-112.
119. De Gennaro, L.; Brunetti, N. D.; Cuculo, A.; Pellegrino, P. L.; & Di Biase, M. (2008). Systemic inflammation in nonischemic dilated cardiomyopathy. Hear Vessel, 23, 445-450.
120. Matsumoto, M.; Tsujino, T.; Lee-Kawabata, M.; Naito, Y.; Sakoda, T.; Ohyanagi, M.; & Masuyama, T. (2010). Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine, 49, 264-268.
121. Kosar, F.; Aksoy, Y.; Ozguntekin, G.; Ozerol, I.; & Varol, E. (2006). Relationship between cytokines and tumour markers in patients with chronic heart failure. European Journal of Heart Failure, 8, 270-274.
122. Wykretowicz, A.; Furmaniuk, J.; Smielecki, J.; Deskur-Smielecka, E.; Szczepanik, A.; Banaszak, A.; & Wysocki, H. (2004). The oxygen stress index and levels of circulating interleukin-10 and interleukin-6 in patients with chronic heart failure. International Journal of Cardiology, 94, 283-287.
123. Eslick, G. D.; Thampan, B. V.; Nalos, M.; McLean, A. S.; & Sluyter, R. (2009). Circulating interleukin-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. International Journal of Cardiology, 137, 81-83.
124. Naito, Y.; Tsujino, T.; Fujioka, Y.; Ohyanagi, M.; Okamura, H.; & Iwasaki, T. (2002). Increased circulating interleukin-18 in patients with congestive heart failure. Heart, 88, 296-297.
125. Yamaoka-Tojo, M.; Tojo, T.; Inomata, T.; Machida, Y.; Osada, K.; & Izumi, T. (2002). Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. Journal of Cardiac Failure, 8, 21-27.
126. Osmancik, P.; Teringova, E.; Tousek, P.; Paulu, P.; & Widimsky, P. (2013). Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One, 8, e53860.
127. Francis, G. S.; Benedict, C.; Johnstone, D. E.; Kirlin, P. C.; Nicklas, J.; Liang, C. S.; Kubo, S. H.; Rudin-Toretsky, E.; & Yusuf, S. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation, 82, 1724-1729.
128. Latini, R.; Masson, S.; Anand, I.; Salio, M.; Hester, A.; Judd, D.; Barlera, S.; Maggioni, A. P.; Tognoni, G.; Cohn, J. N.; & Val-He, F. T. I. (2004). The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. European Heart Journal, 25, 292-299.
129. Vergaro, G.; Emdin, M.; Iervasi, A.; Zyw, L.; Gabutti, A.; Poletti, R.; Mammini, C.; Giannoni, A.; Fontana, M.; & Passino, C. (2011). Prognostic value of plasma renin activity in heart failure. The American Journal of Cardiology, 108, 246-251.
130. Vantrimpont, P.; Rouleau, J. L.; Ciampi, A.; Harel, F.; de Champlain, J.; Bichet, D.; Moye, L. A.; & Pfeffer, M. (1998). Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. European Heart Journal, 19, 1552-1563.
131. Cicoira, M.; Zanolla, L.; Franceschini, L.; Rossi, A.; Golia, G.; Zeni, P.; Caruso, B.; & Zardini, P. (2002). Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American Journal of Cardiology, 89, 403-407.
132. Roig, E.; Perez-Villa, F.; Morales, M.; Jimenez, W.; Orus, J.; Heras, M.; & Sanz, G. (2000). Clinical implications of increased plasma angiotensin ii despite ace inhibitor therapy in patients with congestive heart failure. European Heart Journal, 21, 53-57.
133. Goldsmith, S. R.; Francis, G. S.; Cowley, A. W.; Jr.; Levine, T. B.; & Cohn, J. N. (1983). Increased plasma arginine vasopressin levels in patients with congestive heart failure. Journal of the American College of Cardiology, 1, 1385-1390.
134. Szatalowicz, V. L.; Arnold, P. E.; Chaimovitz, C.; Bichet, D.; Berl, T.; & Schrier, R. W. (1981). Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. The New England Journal of Medicine, 305, 263-266.